![Adenovirus](https://webarchive.library.unt.edu/web/20161019033045im_/http://health.mil/~/media/MHS/General%20Images/Immunization%20Healthcare/Vaccine%20Disease%20Images/adeno.ashx)
Adenoviruses most commonly cause respiratory illness. The illnesses can range from the common cold to pneumonia, croup, and bronchitis. Depending on the type, adenoviruses can cause other illnesses such as gastroenteritis, conjunctivitis, cystitis, and, less commonly, neurological disease.
More than 50 types of immunologically distinct adenoviruses can cause infections in humans. They are relatively resistant to common disinfectants and many environmental conditions such as surfaces, objects and water of swimming pools and small lakes. Infants and people with weakened immune systems are at high risk for developing severe illness caused by adenovirus infection.
A live, oral vaccine against adenovirus types 4 and 7 was approved by the U.S. Food and Drug Administration in March 2011 for U.S. military personnel only, ages 17 through 50 years old. The Department of Defense is the sole user of the vaccine, which is given military recruits entering basic training.
Source: Centers for Disease Control and Prevention
Frequently Asked Questions
Q1:
What are adenoviruses?
A:
Adenoviruses are medium-sized, nonenveloped icosohedral viruses containing double-stranded DNA. There are at least 52 immunologically distinct types that can cause human infections. Adenoviruses are unusually stable to chemical and physical agents and to adverse pH conditions, thus allowing for prolonged survival outside of the body.
Q2:
Can adenoviruses cause acute respiratory disease?
A:
Yes. In the United States, acute respiratory disease is often associated with adenovirus Types 4, 7, and 14. The epidemiology of adenoviruses vary by type; all are transmitted by direct contact, fecal-oral transmission, and occasionally waterborne transmission. Some types can establish persistent asymptomatic infections in tonsils, adenoids, and intestines of infected individuals, and viral shedding can occur for months or years.
Q3:
What are the symptoms of adenovirus infection?
A:
Adenoviruses cause a wide range of illnesses, depending on the virus type. Adenovirus types 4 and 7 can cause respiratory (breathing) problems, fever, sore throat, cough, eye infections, runny nose, headache, and pneumonia. The incubation period of the disease is 4 to 5 days. These symptoms can last up to 10 days. Young infants and especially patients with compromised immune systems are more susceptible to severe complications of adenovirus infection.
Q4:
Can adenovirus be prevented?
A:
Yes. Strict attention to good infection-control practices, including contact and droplet precautions is effective for stopping nosocomial outbreaks of adenovirus associated disease. Frequent handwashing is effective for preventing the spread of adenoviruses. Additionally, there is a U.S. Food and Drug Administration (FDA) approved/licensed vaccine for adenovirus types 4 and 7. Adenovirus types 4 and 7 can be prevented with a single vaccine dose administered as two live, oral enteric-coated tablets (type 4 - white tablet, type 7- light peach tablet).
Q5:
Are respiratory infections a problem for military populations?
A:
Acute infectious respiratory diseases are a significant preventive medicine problem for military populations living in close quarters. Crowded conditions are often found at training centers, dormitories, tent cities, and deployment-staging areas. Other potential transmission environments include recruit training centers, classrooms, dining facilities, and areas where items, such as resuscitation mannequins and water fountains are shared.
Over the past 10 years adenoviruses have affected about 15,000 military basic trainees annually, with 3-4 days of illness per event and 1-2 deaths occurring per year due to the virus. The United States military processes thousands of recruits each year who arrive from all regions of the country as well as some foreign countries, and from a variety of different environments. The recruits are then formed into close-quartered military units. They may arrive as hosts or with mild cases of respiratory infections endemic to their own particular region of the country; they are housed in close contact with individuals from other parts of the country who may be susceptible. New recruits may also be exposed to respiratory infections that are endemic to the recruit training center. Close contact, coupled with the unique stressors of military operations, often put military recruits at a greater risk for respiratory disease than other cohorts.
Q9:
What side effects have been reported with the adenovirus vaccine?
A:
A vaccine, like any medicine, could cause a serious reaction. But the risk of a vaccine causing serious harm, or death, is extremely small. Several mild problems were reported within 2 weeks of getting the vaccine: headache, upper respiratory tract infection (about 1 person in 3), stuffy nose, sore throat, joint pain (about 1 person in 6), abdominal pain, cough, nausea (about 1 person in 7), diarrhea (about 1 person in 10), and fever (about 1 person in 100). More serious problems have been reported by about 1 person in 100, within 6 months of vaccination. These problems included: blood in the urine or stool, pneumonia, and inflammation of the stomach or intestines. It is not clear whether these common or serious adverse events were caused by the vaccine or occurred after vaccination by chance.
Q10:
How effective is the adenovirus vaccine?
A:
Large-scale studies of the new vaccine in U.S. military recruits showed high efficacy rates in preventing wild type 4 adenovirus-associated febrile acute respiratory disease and inducing neutralizing antibody to type 7 adenovirus.
Q11:
What are the components of the adenovirus vaccine?
A:
The adenovirus vaccine contains viable, selected strains of human adenovirus Type 4 and human adenovirus Type 7 prepared in human-diploid fibroblast cell cultures (strain WI-38). The virus strains have not been attenuated. The cells are grown and the virus growth maintained in Dulbecco's Modified Eagle's Medium, fetal bovine serum, and sodium bicarbonate.
Q12:
How is the vaccine administered?
A:
Adenovirus vaccine types 4 and 7 are tablets and are given orally. Each tablet must be swallowed whole and cannot be chewed or crushed. Postpone administration to individuals with vomiting and/or diarrhea and those with moderate to severe acute illness.
Q13:
How many doses of adenovirus vaccine are needed?
A:
A single dose is needed, which consists of two live, oral enteric-coated tablets (type 4 - white tablet, type 7- light peach tablet). Adenovirus vaccine types 4 and 7 is administered only once and no booster dose is required.
Q15:
How is the vaccine stored?
A:
The vaccine must be refrigerated between 2° and 8°C (35° and 46° F) and never frozen. All bottles must be protected from moisture and remain tightly closed. The desiccant canister should not be removed from the bottle.
Q17:
Who should NOT receive this vaccine?
A:
Individuals with known severe allergic reactions to any components of the vaccine; females considering pregnancy within 6 weeks of receiving the vaccine; individuals incapable of swallowing an entire tablet, whole, without chewing should not receive the vaccine.
Q18:
Are there any warnings or precautions associated with the vaccine?
A:
Yes. Vaccinees should use precaution when around children 7 years of age and younger, immunocomprised individuals and pregnant women during the 28 days following vaccination. Because the vaccine contains live adenovirus that is shed in the stool for up to 28 days following vaccination, strict hand washing and personal hygiene is required to minimize risk of transmitting or infecting others with the virus.
Q20:
Is pregnancy testing necessary before administration of the adenovirus vaccine?
A:
Pregnancy testing is part of a routine serology panel for newly enlisted female recruits upon accession because pregnancy is a disqualifying condition for basic training. Do not delay vaccination pending routine recruit pregnancy testing unless pregnancy is suspected. If a female recruit has a positive HCG do not administer live vaccines including adenovirus vaccine and refer the female for follow-up per Service policy. Verbal screening for pregnancy in non-recruit populations is standard practice before administering of live vaccines.
Q21:
Is HIV a contraindication for the adenovirus vaccine?
A:
No. However, the safety and effectiveness of the Adenovirus Types 4 and 7 Vaccine, Live, Oral in immunocompromised individuals has not been evaluated. A documented negative HIV test is not required before administering live vaccines when the vaccinee is screened for immunocompromising conditions. Verbally screen individuals for HIV/AIDS, medical conditions, and/or medications that may affect the immune system before administering the adenovirus vaccine.
You also may be interested in...
Showing results 1 - 15
Page 1 of 2
Publication
11/24/2015
Teva Women's Health issued information on the 36 month expiration of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral (See Image on Message under Additional Documentation/Attachment). Reason: Completion of the 36 stability studies on Adenovirus Type 4 and Type 7 Vaccine, Live, Oral.
Recommended Content:
Adenovirus
Publication
11/24/2015
Recommended Content:
Adenovirus
Publication
10/7/2015
This info paper provides instructions for addressing chewed Adenovirus Type 4 and Type 7 Vaccine, Live, Oral tablets.
Recommended Content:
Adenovirus
Publication
10/5/2015
This info paper describes the adenoviral infection and the vaccine used to prevent it.
Recommended Content:
Adenovirus
Publication
7/2/2014
Recommended Content:
Adenovirus
Publication
6/11/2014
Vaccine information sheet published by the Centers for Disease Control and Prevention about the Adenovirus
Recommended Content:
Adenovirus
Publication
4/1/2014
Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is a vaccine indicated for active immunization for the prevention of febrile acute respiratory disease caused by Adenovirus Type 4 and Type 7. Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is approved for use in military populations 17 through 50 years of age.
Recommended Content:
Adenovirus
Publication
8/4/2012
Operational Infectious Diseases, Naval Health Research Center
Recommended Content:
Adenovirus
Brochure
10/24/2011
The DoD Adenovirus Vaccine Training curriculum is an online course that will provide Military Healthcare Personnel with important and comprehensive information concerning the adenovirus vaccine. It is designed to prepare healthcare personnel to administer adenovirus vaccinations and perform required administrative tasks in support of the DoD's Adenovirus Program.
Recommended Content:
Adenovirus
Policy
- Identification #: N/A
- Date: 8/12/2011
- Type: Guidelines
- Topics:
Adenovirus
Form/Template
7/26/2011
ADENOVIRUS Type 4 and Type 7 LIVE, ORAL VACCINE
ADMINISTRATION COMPETENCY ASSESSMENT
Patient Population Served: Recruits (17-50 yrs)
Recommended Content:
Adenovirus
Publication
7/26/2011
IMPLEMENTATION OF ADENOVIRUS TYPES 4 AND 7, LIVE, ORAL PROGRAM A. IMMUNIZATIONS AND CHEMOPROPHYLAXIS, COMDTINST M6230.4 (SERIES) 1.
Recommended Content:
Adenovirus
Showing results 1 - 15
Page 1 of 2